D-dimer testing to determine the duration of anticoagulation therapy  by Palareti, G. et al.
women with sphingomyelin levels of 60 mg/dL than in women with
sphingomyelin levels of 39 mg/dL. This association did not remain
significant after multivariant adjustment for standard cardiovascular risk
factors. Men with sphingomyelin levels of 60 mg/dL had higher calcium
scores (135 vs 99 Agatston units, P  .01) than men with sphingomyelin
levels 39 mg/dL.
Comment: Sphingomyelin accumulates in atheromas in animal models
and in human atheroma. Much sphingomyelin found in arteries arises from
synthesis within the arterial tissue (Circulation 1961;23:370-5). However,
synthesis of sphingomyelin within arterial tissue appears slow compared with
the total amount accumulated, suggesting plasma levels of sphingomyelin
may also contribute to accumulation of sphingomyelin within arterial tissue.
The unadjusted data from this study provide some support that plasma
sphingomyelin is a component of a pathway that mediates risk for subclinical
disease attributable to traditional cardiovascular risk factors.
Results of endovascular repair of the thoracic aorta with the Talent
Thoracic stent graft: the Talent Thoracic Retrospective Registry
Fattori R, Nienaber CA, Rousseau H, et al. J Thorac Cardiovasc Surg
2006;132:332-9.
Conclusion: The Talent thoracic stent graft appears effective in the
treatment of both acute and chronic diseases of the thoracic aorta.
Summary: This report derives from the Talent Thoracic Retrospective
Registry. It includes treatment of patients in seven major European referral
centers during an 8-year period. The Talent thoracic stent graft was used to
treat thoracic aortic pathology in 457 consecutive patients, of which 113
were emergent cases and 344 were elective. Median follow-up was 24  19
months (range, 1 to 85.1 months). Follow-up was based on clinical and
imaging findings. Adverse events were included, and all adverse events were
reviewed by a single physician.
In-hospital mortality was 5% (23 patients). Mortality was 8.5% during
follow-up of the 422 patients who survived the initial procedure. Thirty-six
patients died, and 11 of the deaths were related to aortic disease. Specific
procedure-related complications included stroke in 3.7%, paraplegia in 1.7%,
and local vascular access-site complications in 3.3%. Two patients died of
aortic rupture during placement of the device.
Persistent endoleak was documented in 64 cases, of which 43 demon-
strated primary endoleak present at the end of the procedure, and 21
endoleaks were discovered during follow-up. There were 7 patients with
persistent endoleak with aortic rupture during the follow-up period. Aortic
rupture associated with persistent endoleak occurred from 40 days to 35
months. All patients with aortic rupture associated with persistent endoleak
died. Stent graft migration occurred in seven cases, graft fabric failure in two,
and known modular disconnection in three. Survival was 90.97% at 1 year,
85.36% at 3 years, and 77.49% at 5 years. Freedom from a second procedure,
endovascular, or open conversion, at 1, 3 and 5 years was 92.41%, 81.3%,
and 70.0%, respectively.
Comment: These are registry data and are thus subject to all the limita-
tions of such data. Patients were treated for a variety of acute and chronic
conditions. Although patients were acquired during an 8-years period, only 95
patients had 3 years of clinical and imaging follow-up available. The data
suggest the Talent thoracic aortic stent graft can be deployed with a reasonable
rate of complications for a variety of thoracic aortic pathologies. Further
follow-up is obviously required to establish long-term efficacy.
A prospective analysis of fenestrated endovascular grafting: intermediate-
term outcomes
O’Neill S, Greenberg RK, Haddad F, et al. Eur J Vasc Endovasc Surg
2006;32:115-23.
Conclusion: Abdominal aortic stent grafts can be placed with graft
material incorporated around visceral arteries with effective prevention of
aneurysm rupture and minimal loss of visceral artery patency.
Summary: The study included patients with abdominal aortic aneu-
rysm (AAA) with short proximal necks who were considered high risk for
open repair and unacceptable for conventional endovascular repair. Fenes-
trated devices were individually designed from reconstructed computed
tomography (CT) data using the Cook Zenith graft as the device platform.
The design of each graft required knowledge of the ostial diameter of each
visceral vessel, relative distances from a fixed landmark (usually the superior
mesenteric artery), and radial orientation of the visceral ostial. Small fenes-
trations were placed between stent struts and could be used in conjunction
with a visceral artery stent. Larger fenestrations (8 to 12 mm in diameter)
could be placed with a stent strut crossing an ostium and were not intended
for use with visceral artery stents. Scalped fenestrations, hemi-oval in shape,
were in the most proximal portion of the fabric. Patients were followed-up
with CT scan, duplex ultrasound imaging, and plain abdominal radiographs
at hospital discharge, at 1, 6 and 12 months, and then annually thereafter.
Between 2001 and 2005, 119 patients were treated. Their mean age
was 75 years, and the mean aneurysm size was 65 mm. There were 302
visceral vessels inferior to the fabric seal, with a mean of 2.5 vessels per
patient. Fifty-eight percent of the grafts incorporated two venal arteries and
the superior mesenteric artery. There was no acute visceral artery loss at the
time of the graft implantation. Mean follow-up was 19 months (range, 0 to
42 months). One death occurred30 days of device implantation. Survival
by Kaplan-Meier analysis at 1, 12, 24, and 36 months was 99%, 92%, 83%,
and 79%, respectively. There were no conversions, and no known aneurysm
ruptures have occurred. There were 11 type 1 endoleaks at discharge. The
endoleak rate was 10% at 30 days, and all were type 2. At 2 years, fenestra-
tions had decreased 5 mm in diameter in 77% of cases. During follow-up,
10 of 231 renal artery stents occluded, with three occlusions before dis-
charge. There were 12 additional renal artery stent stenoses. Three patients
had permanent dialysis.
Comment:Outside of a few selected centers, progress has been slow in
the development of fenestrated endovascular grafts. This is likely because the
grafts must be individually designed and a high level of technical skill is
required for successful placement. Acceptance of this technology will also
require conclusive evidence that the graft body itself does not migrate. As
pointed out by the authors, even minimum migration of a fenestrated graft
will result in significant renal and mesenteric artery complications.
Endarterectomy versus stenting in patients with symptomatic severe
carotid stenosis
Mas J-L, Chatellier G, Beyssen B; and the EVA-3S Investigators. New Engl
J Med 2006;355:1660-71.
Conclusion: Compared with carotid artery stenting (CAS), carotid
endarterectomy (CEA) in patients with symptomatic carotid stenosis of
60% to 99% provides lower rates of stroke and death at 1 and 6 months.
Summary:This was a randomized, publicly funded, noninferiority trial
conducted in 10 nonacademic and 20 academic medical centers in France.
Eligible for the trial were patients with symptomatic carotid stenosis, defined
as retinal or hemispheric transient ischemic attacks or a nondisabling stroke
occurring 120 days from study enrollment, and who had 60% to 99%
carotid stenosis. Confirmation of stenosis was by contrast angiography or a
combination of duplex scanning and magnetic resonance angiography.
Patients had to be suitable candidates for either CEA or CAS. All evaluations
were performed by neurologists at 48 hours, 30 days, and 6 months after
treatment, and every 6 months thereafter. The primary end point was stroke
or death 30 days of treatment.
The Data Safety and Monitoring Committee stopped this trial after
inclusion of 527 patients for reasons of both safety and futility. The 30-day
incidence of any stroke or death after CEA was 3.9% (95% confidence
interval [CI], 2.0% to 7.2%). After stenting, the 30-day incidence of stroke or
death was 9.6% (95% CI, 6.4% to 14.0%). The relative risk of any stroke or
death after stenting was 2.5 times that of CEA (95% CI, 1.2 to 5.1). There
was a 1.5% incidence of disabling stroke after CEA (95% CI, 0.5% to 4.2%)
and a 3.4% incidence of disabling stroke after CAS (95% CI, 1.7% to 6.7%).
The relative risk of disabling stroke in stented patients vs patients undergo-
ing CEA was 2.2 (95% CI, 0.7 to 7.2). The incidence of any stroke or death
6months was 6.1% after CEA and 11.7% after stenting (P .02). CAS had
more local major complications, and CEA had more systemic major compli-
cations (mainly pulmonary). Differences were not significant. Cranial nerve
injury was more common after CEA than after CAS.
Comment: This was a publicly funded, prospective, randomized trial.
It has the great benefit of not being tainted by industry sponsorship. There
was a lower-than-predicted stroke and death rate for CEA and a higher-than-
predicted stroke and death rate for CAS. A criticism of the trial will obviously
be a possible learning curve effect in the stented patients and the continuing
evolving of CAS techniques and devices. This study is far cleaner than the
SAPPHIRE trial (New Engl J Med 2004;351:1493-501) that was used to
generate United States Food and Drug Administration approval of CAS for
symptomatic high-risk patients. At the very least, the current trial raises
serious concern about the relative safety of CAS in symptomatic patients of
standard surgical risk. Given current data, it remains that the only patients
who should undergo CAS outside of a clinical trial are very high-risk patients
with symptomatic stenosis. Determination of high surgical risk should be by
a multidisciplinary team that is able to evaluate perioperative systemic and
surgical risk. It is not acceptable or ethical for high surgical risk to be
determined by individuals who are only capable of performing carotid stents
or who have financial incentives to participate in industry-sponsored trials.
D-dimer testing to determine the duration of anticoagulation therapy
Palareti G, Cosmi B, Legnani C, and the PROLONG Investigators. N Engl
J Med 2006;355:1780-9.
Conclusion: An abnormal D-dimer level 1 month after discontinua-
tion of anticoagulation for a first time episode of venous thromboembolism
(VTE) is a marker for increased risk of VTE recurrence that can be reduced
by reinstituting anticoagulation.
Summary: There is a trend towards individualization of duration of
anticoagulation for VTE. Patients are now stratified to whether the VTE
episode was provoked, such as after trauma or surgery or another known risk
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factor, or was idiopathic, which includes patients with known and unknown
thrombophilias. The proper duration of anticoagulation for patients with
idiopathic VTE is unknown. It was postulated that D-dimer testingmight be
used to stratify patients for length of anticoagulation after idiopathic VTE.
The authors performed D-dimer testing 1 month after anticoagulation
was discontinued in patients who had a first time, unprovoked episode of
VTE (deep venous thrombosis or pulmonary embolism). Patients had
received anticoagulation with warfarin for at least 3 months after their
diagnosis of VTE. Patients with normal D-dimer levels 1 month after
discontinuation of anticoagulation were not continued on anticoagulation.
Patients with abnormal D-dimer levels were randomly assigned to either
resume anticoagulation or continue without anticoagulation. The primary
end point was a composite of major bleeding and recurrent VTE. Average
follow-up was 1.4 years.
The study comprised 608 patients, and 223 (36.7%) had an abnormal
D-dimer level 1 month after discontinuation of anticoagulation. Of these
223 patients, 120 stopped anticoagulation and 18 (15%) had a recurrent
VTE event. There were 103 patients who resumed anticoagulation, and
three had a recurrent VTE event (2.9%). The adjusted hazard ratio was 4.26
(95% confidence interval, 1.23 to 14.6; P  .02) favoring resumption of
anticoagulation. In the 385 patients with a normal D-dimer level, 24 had a
recurrent VTE event (6.2%). The adjusted hazard ratio for recurrent VTE
among patients who stopped anticoagulation and who had an abnormal
D-Dimer level compared with those with normal D-dimer levels was 2.27
(95% CI, 1.15 to 4.46; P  .02).
Comment: Evidence is accumulating that D-dimer levels can be used
to predict risk of recurrent VTE after an initial idiopathic VTE (Thromb
Haemost 2002;87:7-12 and Circulation 2003;108:313-8). The 6.2% VTE
recurrence rate in the patients with normal D-dimer level after 3 months of
anticoagulation, along with previous data, suggest 3 months of anticoagu-
lation is inadequate for patients with idiopathic VTE. A more conservative
approach would be 6 months of anticoagulation after idiopathic VTE,
followed by D-dimer testing. If the D-dimer level is abnormal, resumption
of anticoagulation may be indicated.
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 1 Abstracts 219
